Last reviewed · How we verify
Low Bup/Nal Dose
A combination of buprenorphine (partial opioid agonist) and naloxone (opioid antagonist) at reduced doses to treat opioid use disorder with potentially improved safety and tolerability.
A combination of buprenorphine (partial opioid agonist) and naloxone (opioid antagonist) at reduced doses to treat opioid use disorder with potentially improved safety and tolerability. Used for Opioid use disorder.
At a glance
| Generic name | Low Bup/Nal Dose |
|---|---|
| Also known as | Suboxone |
| Sponsor | New York State Psychiatric Institute |
| Drug class | Opioid agonist-antagonist combination |
| Target | Mu-opioid receptor (buprenorphine); opioid receptors (naloxone antagonism) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Substance Use Disorder |
| Phase | Phase 3 |
Mechanism of action
Buprenorphine acts as a partial agonist at the mu-opioid receptor, providing sufficient opioid activity to prevent withdrawal while having a ceiling effect on respiratory depression. Naloxone is included to discourage intravenous misuse by precipitating withdrawal if injected. The low-dose formulation aims to optimize the risk-benefit profile for opioid use disorder treatment.
Approved indications
- Opioid use disorder
Common side effects
- Headache
- Nausea
- Constipation
- Insomnia
- Withdrawal symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |